Recombinant SARS-CoV-2 Nucleocapsid His-tag Protein, CF

Catalog #: 11033-CV Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
11033-CV-100

Recombinant SARS-CoV-2 Nucleocapsid His-tag Protein SDS-PAGE.

1 Image

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant SARS-CoV-2 Nucleocapsid His-tag Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Bioassay data are not available.

Source

Spodoptera frugiperda, Sf 21 (baculovirus)-derived sars-cov-2 Nucleocapsid protein
Met1-Ala419 (Thr205Ile), with a C-terminal 6-His tag

Accession #

YP_009724397.2

N-terminal Sequence
Analysis

Protein identity confirmed by mass spectrometry.

Predicted Molecular Mass

46 kDa

SDS-PAGE

45-55 kDa, under reducing conditions.

Product Datasheets

11033-CV

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

11033-CV

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

SDS-PAGE

View Larger

2 μg/lane of Recombinant SARS-CoV-2 Nucleocapsid His-tag Protein (Catalog # 11033-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 45 - 55 kDa.

Reconstitution Calculator

Background: Nucleocapsid

SARS-Cov-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). While the S, E and M proteins build up the viral envelop, the N protein is involved transcription, replication and packaging of the viral RNA genome into a helical ribonucleocapsid (RNP) (2, 3). The SARS-Cov-2 N protein is a ~45 kDa protein composed of two independent structural domains connected by a linker region. The N-terminal region contains an RNA binding domain, the linker region interacts with the M protein and the C-terminal region contains a self-association domain (2,3). The SARS-Cov-2 N protein shares 91% and 47% amino acid sequence identity with SARS-Cov-1 and MERS N protein, respectively. The SARS-Cov-2 N protein displays VSR (viral suppressor of RNA interference) activity in mammalian cells (4). Several emerging SARS-CoV-2 genomes have been identified with mutations compared to the Wuhan-Hu-1 SARS-CoV-2 reference sequence. As the N protein is an abundant protein during coronavirus infection and displays high immunogenic activity (5, 6), it has been used to develop diagnostic kit for detecting IgM and IgG antibodies against SARS-Cov-2 (7). Within the N protein, the T205I mutation has been identified in the B.1.351 and B.1.621 variants and it might make an attractive target for the development of antiviral therapeutics or potential diagnostic tools.

References